These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35965524)

  • 1. Identification and Validation of METTL3-Related Molecules for Predicting Prognosis and Efficacy of Immunotherapy in Gastric Cancer Based on m6A Methylome and Transcriptome Sequencing Analysis.
    Chen S; Su X; Wang J; Zheng N; Tang Y; Peng G; Dong R; Lu F; Liu M; Zhao Y; Wu H
    Front Oncol; 2022; 12():935239. PubMed ID: 35965524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative proteomics and m6A microarray analyses of the signatures induced by METTL3 reveals prognostically significant in gastric cancer by affecting cellular metabolism.
    Peng G; Chen S; Zheng N; Tang Y; Su X; Wang J; Dong R; Wu D; Hu M; Zhao Y; Liu M; Wu H
    Front Oncol; 2022; 12():996329. PubMed ID: 36465351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 6. Depicting the Profile of METTL3-Mediated lncRNA m6A Modification Variants and Identified SNHG7 as a Prognostic Indicator of MNNG-Induced Gastric Cancer.
    Liu T; Feng Y; Yang S; Ge Y; Zhang T; Li J; Li C; Ruan Y; Luo B; Liang G
    Toxics; 2023 Nov; 11(11):. PubMed ID: 37999596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine methylation regulates the tumor microenvironment of Epstein-Barr virus-associated gastric cancer.
    Zhang Y; Zhou F; Zhang MY; Feng LN; Guan JL; Dong RN; Huang YJ; Xia SH; Liao JZ; Zhao K
    World J Gastrointest Oncol; 2024 Jun; 16(6):2555-2570. PubMed ID: 38994134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.
    Jing JJ; Zhao X; Li H; Sun LP; Yuan Y
    Future Oncol; 2021 Jul; 17(20):2605-2620. PubMed ID: 33878934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
    Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
    Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
    [No Abstract]   [Full Text] [Related]  

  • 18. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
    Yang DD; Chen ZH; Yu K; Lu JH; Wu QN; Wang Y; Ju HQ; Xu RH; Liu ZX; Zeng ZL
    Front Oncol; 2020; 10():115. PubMed ID: 32175271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.